• Custom Health posted Q1-2026 revenue of US$4.3 million, up 5%, as IFRS net loss widened to US$8.5 million.
• Adjusted EBITDA loss deepened to US$5.3 million, while gross margin rose 3.8 percentage points to 48.6%.
• Including InnovativeRx, consolidated quarterly revenue totaled US$12.9 million, implying a proforma annualized revenue run-rate of US$51.6 million.
• InnovativeRx delivered Q2-2026 revenue of US$8.6 million, up 10.5%, with adjusted EBITDA of US$0.6 million.
• Shares began trading on the TSX on June 24 under CHLT; Custom Health received US$9.6 million from subscription receipt conversions and lined up up to US$50 million in financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Custom Health Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607030600NEWSFILECNPR____20260703_303898_1) on July 03, 2026, and is solely responsible for the information contained therein.